CARM1 and AL amyloidosis: MS049, TP-064, and EZM2302 exhibit the highly selective inhibition of CARM1 (PRMT4) (51), and the latter two compounds can be effectively used to treat multiple myeloma (MM) by selectively blocking CARM1 (90, 91).